95 results on '"Sauzullo, Ilaria"'
Search Results
2. Changes in T cell effector functions over an 8-year period with TNF antagonists in patients with chronic inflammatory rheumatic diseases
3. Multifunctional flow cytometry analysis of CD4+ T cells as an immune biomarker for latent tuberculosis status in patients treated with TNF antagonists
4. Mycobacterial INFgamma release variation during long- term treatment with TNF blockers: lack of correlation with clinical outcome
5. Severe and Persistent Depletion of Circulating Plasmacytoid Dendritic Cells in Patients with 2009 Pandemic H1N1 Infection
6. PHARMACOLOGICAL MODULATION OF APOPTOSIS OF PBMC BY DARUNAVIR AND MARAVIROC
7. Prospective randomized crossover study on the performance of QuantiFERON®-TB Gold In-Tube test for screening and monitoring of latent tuberculosis infection across patients undergoing anti-TNF treatment
8. THE PERFORMANCE OF INTERFERON-G RELEASE ASSAYS (IGRAS) FOR TB DETECTION IS IMPAIRED IN HIV LATE PRESENTATION
9. HORMONAL STATUS AND NATURAL IMMUNITY IN HIV INFECTED PATIENTS
10. Multifunctional Analysis of CD4+T-Cell Response as Immune-Based Model for Tuberculosis Detection
11. Randomized prospective crossover study evaluating the performance of Quantiferon TB Gold In-Tube in patients undergoing anti-TNF alpha treatment for screening and monitoring of latent tuberculosis infection
12. 'Usefulness of interferon-gamma release assays for latent tuberculosis screening in patients candidate for TNF-g therapy'
13. 'IGRAs assay for the screening of latent TB infection in patients candidate for TNF-α antagonist'
14. Study of intracellular and immunomodulant effects of CCR5 Antagonist Maraviroc
15. Effect in vitro of CCR5 Antagonists on Innate Immune System: Maraviroc Inhibits the Migration of Neutrophils, Macrophages, and DC
16. Down-regulation in vitro of Matrix Metalloproteinase-9 in Rat Astrocytes by CCR5 Antagonist Maraviroc: Potential Therapeutical Implication for HIV-associated Neurologic Disease
17. 'In vitro Effect of CCR5 Antagonists on Innate Immune System: Maraviroc Inhibits the Migration of Neutrophils, Macrophages and Dendritic Cells'
18. Study of the Immunomodulant Effect of New Class of Antretroviral Drugs: Downregulation of Cell Migration by Maraviroc
19. TLR7 Signaling and IFN-α Production by pDC: Potential Target for Immunotherapy
20. 'Utility of QuantiFERON-TB Gold in-tube for Tuberculosis screening in Italian Air Force personel'
21. Detection of IL-2 in addition to IFN-gamma discriminates active tuberculosis patients, latently infected individuals and controls
22. 'Detection of M. tuberculosis infection by Interferon-g Release Assays: a comparative study in HIV-infected patients and in immunosuppressed people candidates for anti-TNF-a therapy'
23. ROLE OF INTERFERON-Gamma RELEASE ASSAYS (IGRAS) IN HIV-SSOCIATED TUBERCULOSIS: IN VITRO AND IN VIVO EFFECT OF ANTITUBERCULOUS DRUGS
24. 'TLR7 signaling and IFN-a production by pDC: potential target for immunoterapy '
25. Biomarkers for active tuberculosis (TB) infection: potential role of IFN-g-inducible protein 10 (IP-10)-based assay'
26. Role of pDC and mDC assessement in the management of HIV infection during antiretroviral therapy'
27. Dynamics of specific IFN-g T-cell responses during antituberculous treatment'
28. 'Studio cross-over prospettico randomizzato di confronto tra Quantiferon TB Gold e Test secondo Mantoux nei pazienti candidati al trattamento con farmaci biologici antagonisti del TNFα'
29. 'CXCL10/IP10: biomarker alternativo nella diagnosi dell’infezione tubercolare'
30. 'Interferon-g Release Assays (IGRAs) for Detection and Treatment Response of Tuberculosis in Patients with HIV Infection'
31. 'Role of Interferon-γ Release Assays (IGRAs) in HIV-Associated Tuberculosis: in Vitro and in Vivo Effect of Antituberculous Drugs'
32. 'Interferon-g release assay (IGRA) nello screening della tubercolosi latente nei pazienti candidati al trattamento con antagonisti del TNFα'
33. DIVERGENT ROLE FOR DENDRITIC CELLS IN VIRAL CONTROL AND CHRONIC INFLAMMATION IN HIV DISEASE
34. Il QuantiFERON-TB Gold nel monitoraggio terapeutico dell’infezione tubercolare
35. Valutazione del cxcl10/ip10 come biomarker alternativo in pazienti con TUBERCOLOSI attiva E TEST quantiferon-GOLD negativo
36. Impatto della terapia antitubercolare sul rilascio di interferon-GAMMA al test QUANTIFERON-TB GOLD'
37. Diagnosi rapida di infezione da Micobatteri atipici su campioni respiratori
38. 'Study of the genotypic resistant pattern in HIV-infected women and children from rural west Cameroon' Antonelli
39. Test immunologici nello screening di infezione da M. tuberculosis in pazienti hiv positivi
40. Effect of Antituberculosis Treatment on Specific Interferon-γ T-Cell Responses
41. Il QUANTIFERON-TB GOLD come parametro predittivo di infezione tubercolare recidivante'
42. Study of the genotypic-resistant pattern in plasma of a group of HIV-infected Cameroonian pregnant women and children
43. Rapida diagnosi di infezione da Mycobatteri atipici: utilizzo dei kit Arnika su campioni respiratori
44. Utilità clinica del QUANTIFERON –TB GOLD nel monitoraggio terapeutico in corso di tubercolosi
45. Effetto in vitro ed ex vivo dei farmaci antitubercolari sul rilascio di IFN-gamma
46. 'Serological profile in identical twins discordant for multiple sclerosis'
47. Ruolo prognostico degli anticorpi anti-R7V in pazienti HIV+
48. Screening dell’infezione tubercolare latente con Quantiferon® TB Gold nei militari impiegati in teatri operativi ad alta endemia – Dati preliminari
49. Utilizzo del Quantiferon TB-Gold in una coorte di soggetti pediatrici e HIV positivi
50. Infezione da M. tuberculosis: applicazione clinica del test Quantiferon (QF)-TB Gold
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.